Abstract
- In 2019, a cohort study conducted in Quebec, Canada, including about 45 000 children exposed to the combination of doxylamine + pyridoxine during the first trimester of pregnancy for an average of 4 weeks, showed a roughly 7% increase in the incidence of major birth defects and a roughly twofold increase in spina bifida, compared with children not exposed in utero to an antiemetic drug. Despite the methodological precautions taken by the study's authors, a risk of bias exists.
- No particular risk was identified in meta-analyses of earlier, less highly powered studies. A number of case-control studies have shown associations with specific malformations, including spina bifida, pyloric stenosis, and congenital heart defects.
- In practice, when non-pharmacological measures are insufficient for relieving non-serious but very troublesome vomiting during pregnancy, doxylamine remains the first-choice antiemetic drug, in the absence of a better alternative. It is important to inform the patient of the concerns over the risk of malformations and the lack of a less dangerous alternative drug, and to determine, in conjunction with the patient, the lowest possible daily dose and the shortest possible treatment duration that provide acceptable relief.
©Prescrire 1 November 2020
Source: "Doxylamine during pregnancy: minimise dose and duration, due to possible link with malformations" Prescrire International 2020; 29 (220): 267-269. Subscribers only.
Enjoy full access to Prescrire International, and support independent information
|